 NEW YORK, NY ACCESSWIRE August 5, 2021 Kadmon Holdings, Inc. NASDAQ:KDMN today provided a business update and reported financial and operational results for the second quarter of 2021. The recent U.S. FDA approval of REZUROCK marked a transformative event for Kadmon and for patients living with cGVHD. 